As the successor to Chindex's Medical Products division, the Joint Venture will market, sell and service medical products manufactured by various major multinational companies, including Siemens AG, Hologic, Candela, Cutera and Intuitive Surgical, for which the Joint Venture will be the distribution partner for the sale and servicing of color ultrasound systems, mammography, aesthetic lasers and surgical robotic systems, respectively. It also will arrange financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank.  Upon investiture, Fosun Pharma will contribute its medical device business, excluding clinical diagnostic products and including dental products and consumables, surgical consumables including sutures and needles, and disposable transfusion supplies.

Chindex references its Current Report on Form 8-K filed today with the Securities and Exchange Commission that contains additional information regarding the Joint Venture and related agreements, terms and conditions.

Financial Impact of the Transaction

Chindex no longer will consolidate the operations of its Medical Products division in its financial statements.  Going forward, Chindex will report its 49% investment in the Joint Venture via the equity method, and will recognize income or loss from the Joint Venture as it is incurred.

SOURCE Chindex International, Inc.